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Coronary artery disease and its sequelae—ischemia, myocardial infarction, and heart failure—are leading causes of morbidity and
mortality in man. Considerable effort has been devoted toward improving functional recovery and reducing the extent of infarction after
ischemic episodes. As a step in this direction, it was found that the heart was significantly protected against ischemia–reperfusion injury if it
was first preconditioned by brief ischemia or by administering a potassium channel opener. Both of these preconditioning strategies were
found to require opening of a KATP channel, and in 1997 we showed that this pivotal role was mediated by the mitochondrial ATP-sensitive
K+ channel (mitoKATP). This paper will review the evidence showing that opening mitoKATP is cardioprotective against ischemia–
reperfusion injury and, moreover, that mitoKATP plays this role during all three phases of the natural history of ischemia–reperfusion injury
preconditioning, ischemia, and reperfusion. We discuss two distinct mechanisms by which mitoKATP opening protects the heart-increased
mitochondrial production of reactive oxygen species (ROS) during the preconditioning phase and regulation of intermembrane space (IMS)
volume during the ischemic and reperfusion phases. It is likely that cardioprotection by ischemic preconditioning (IPC) and KATP channel
openers (KCOs) arises from utilization of normal physiological processes. Accordingly, we summarize the results of new studies that focus
on the role of mitoKATP in normal cardiomyocyte physiology. Here, we observe the same two mechanisms at work. In low-energy states,
mitoKATP opening triggers increased mitochondrial ROS production, thereby amplifying a cell signaling pathway leading to gene
transcription and cell growth. In high-energy states, mitoKATP opening prevents the matrix contraction that would otherwise occur during
high rates of electron transport. MitoKATP-mediated volume regulation, in turn, prevents disruption of the structure–function of the IMS and
facilitates efficient energy transfers between mitochondria and myofibrillar ATPases.
D 2003 Elsevier B.V. All rights reserved.Keywords: Adenosine triphosphate; Mitochondrion; Heart; ATP-sensitive potassium channel; Ion channel gating; Myocardial infarction; Ischemic
preconditioning; Myocardial
1. Introduction toward understanding the roles and mechanisms of mito-The mitochondrial ATP-sensitive K+ channel (mitoKATP)
has been a major focus of our research, and we have
reviewed its basic properties in the previous paper [1]. A
surprising outcome of these studies was the discovery that
mitoKATP is the receptor for KATP channel openers (KCOs)
that protect the heart against ischemia–reperfusion injury
[2]. This finding led to a flurry of scientific activity directed0005-2728/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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E-mail address: garlid@pdx.edu (K.D. Garlid).KATP in cardioprotection, and these will be reviewed here in
some detail. Because cardioprotection employs normal
physiological pathways and processes, we will also discuss
the physiological roles of mitoKATP in heart. There has been
some disagreement on the question of when mitoKATP
opening is critical for cardioprotection, and we will review
evidence that mitoKATP plays an important role during all
three phases of preconditioning.
Opening mitoKATP appears to have two distinct conse-
quences, depending on the underlying bioenergetic state.
When the membrane potential (DW) is high, as in the
normoxic, resting heart, K+ influx via mitoKATP causes
matrix alkalinization and a consequent rise in mitochondrial
K.D. Garlid et al. / Biochimica et Biophysica Acta 1606 (2003) 1–212production of reactive oxygen species (ROS) [3]. When DW
is depressed, as occurs during ischemia or inotropy, mito-
KATP opening adds a parallel K
+ conductance pathway to
prevent contraction of the matrix and expansion of the
intermembrane space (IMS) [4,5].
This review will discuss hypotheses for the mechanisms
by which mitoKATP opening protects the heart. Despite its
narrow scope, this review cannot do justice to the many
excellent contributions that have been made in this field of
research. Other reviews are available that cover other
aspects of this rapidly growing field or present a different
perspective [6–14].2. Protecting the heart against ischemia–reperfusion
injury
Preconditioning describes an experimental treatment of
the normal heart that reduces myocardial damage from a
subsequent ischemia–reperfusion event. Preconditioning
involves a series of cell signaling events that take place
prior to ischemia and that modify one or more cellular
components that play a role as end-effectors of protection.
Postconditioning describes treatments that are effective after
reperfusion of the ischemic heart.
2.1. Modes of preconditioning and postconditioning
At least seven different modes of cardioprotection have
been described. (1) Ischemic preconditioning (IPC)
describes the phenomenon in which a brief period of
ischemia protects the myocardium from damage induced
by a subsequent, longer period of ischemia [15]. (2) Calci-
um preconditioning (CPC) describes the phenomenon in
which a transient increase in intracellular calcium protects
the heart against subsequent global ischemia [16–18]. (3)
KCO preconditioning describes the phenomenon in which
administration of a KCO prior to ischemia protects the heart
[19]. The protection afforded by preconditioning is of brief
duration, about 1 h. All three modes of preconditioning
inhibit development of ischemic contracture, improve post-
ischemic functional recovery after reperfusion, and reduce
necrosis and apoptosis. Each mode of preconditioning
mobilizes the cardioprotective signaling pathway discussed
in Section 4.1.
Four additional modes of cardioprotection have been
described: (4) Delayed preconditioning arises as a secondary
event from the first three modes of preconditioning. Thus,
acute protection arises after IPC and disappears after 1–2 h.
Twelve hours later, with no further intervention, cardiopro-
tection begins again, reaching a maximum at 24 h and
lasting until 72 h after the preconditioning ischemia [20–
22]. (5) Adaptive preconditioning (APC) is a long-lasting
cardioprotection arising from chronic hypoxia, including the
hypoxia of gestation and high altitude [23]. (6) Na+/H+
exchange inhibition by agents such as cariporide is alsocardioprotective [24,25]. (7) Ischemic post-conditioning is a
new finding reported by Zhao et al. [26]. The heart under-
goes ischemia and reperfusion without pretreatment. Begin-
ning shortly after reperfusion, the heart is subjected to three
cycles of 30 s ischemia and 30 s reperfusion. Remarkably,
these hearts were protected to the same extent with ischemic
post-conditioning as they were with IPC.
2.2. Cardioprotection by KCOs
Gross et al. [27] observed cardioprotection by nicorandil
before this agent was known to be a KCO. Grover et al. [19]
were the first to evaluate KCOs for their ability to protect
the heart against ischemia–reperfusion injury. They found
cromakalim and pinacidil to be protective in the perfused rat
heart model [19], and subsequently showed that other
KCOs, including bimakalim, aprikalim, and P-1075, also
protected isolated rat hearts [28–30]. Investigators have
demonstrated cardioprotection by KCOs in isolated hearts
from rats, rabbits, ferrets, and guinea pigs [31–36]. Arm-
strong et al. [37] found that KCOs protect isolated rabbit
cardiomyocytes undergoing simulated ischemia, indicating
that the effects are mediated at the level of the cardiomyo-
cyte. Speechly-Dick et al. [38] and Puddu et al. [39] showed
that cromakalim and bimakalim protected hypoxic human
atrial trabecula, suggesting that KATP channels are a clini-
cally relevant pharmacologic target. The protective effects
of KCOs are abolished by KATP channel blockers.
2.3. KATP channels are required for protection by IPC and
CPC
Preconditioning with KCOs mimics IPC, implicating
KATP channels in the mechanism of protection by IPC.
This was shown directly by Gross et al. [40,41], who were
the first to demonstrate that the KATP channel blockers
glibenclamide and 5-hydroxydecanoate (5-HD) block the
cardioprotection of IPC. Further linking these two modes
of protection, Yao and Gross [42] found that a subthresh-
old dose of bimakalim protected ischemic tissue when
combined with a subthreshold ischemic-preconditioning
protocol. KATP blockers have been shown to abolish IPC
in rabbits, rats, pigs, and man [6]. Finally, KATP channels
were shown to be involved in CPC by Kouchi et al. [43],
who showed that protection by CPC is blocked by
glibenclamide.
These studies made it clear that KATP channels play a
central role in all three modes of acute preconditioning. It
was initially believed that opening of sarcolemmal KATP
channels (sarcKATP) was protective because it shortened
action potential duration (APD), thereby reducing Ca2 +
entry to the cytosol. Several features then arose that raised
doubts about this mechanism. In particular, it was shown
that cardioprotection was preserved in conditions where
there was no APD shortening [44,45] (for reviews, see
Refs. [7,10]).
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3.1. The central role of mitoKATP in cardioprotection
Until 1996, it was universally assumed that cardiopro-
tection by IPC, CPC, and KCOs was afforded by opening
sarcKATP. Our laboratory reported three findings that shifted
the focus from sarcKATP to mitoKATP as the key receptor for
cardioprotection. First, we showed that various KCOs open
mitoKATP within their cardioprotective concentration. We
suggested that mitoKATP, rather than sarcKATP, may be the
key player in cardioprotection [46]. Second, we compared
the sensitivities of KATP channels from cardiac sarcolemmaFig. 1. Comparative potencies of cromakalim and diazoxide on KATP
channels from cardiac mitochondria and sarcolemma. The relative flux, DJ/
DJmax, is plotted versus concentrations of diazoxide (Panel A) and
cromakalim (Panel B). Each panel includes data from mitochondrial (.)
and sarcolemmal (o) KATP channels from bovine heart. The KATP channels
were extracted from their respective membranes using Triton-X100,
partially purified, and reconstituted into liposomes. K1/2 values for
diazoxide were 0.8 and 840 AM for mitochondrial and sarcolemmal
channels, respectively. K1/2 values for cromakalim were 1.6 and 18 AM for
mitochondrial and sarcolemmal channels, respectively. Data are taken from
Garlid et al. [2].
Fig. 2. Cardioprotection against ischemia– reperfusion injury by cromaka-
lim and diazoxide. Shown are values of cumulative lactate dehydrogenase
(LDH) release from hearts subjected to 25 min of global ischemia and 30
min of reperfusion. Values are normalized to LDH released in untreated
hearts. LDH release is taken as a measure of cell damage due to ischemia–
reperfusion. Data are taken from Garlid et al. [2].and cardiac mitochondria and showed that cardiac sarcKATP
is essentially insensitive to diazoxide and 5-HD, whereas
mitoKATP is sensitive to both agents [46,47]. Fig. 1 contains
two sets of dose–response curves for cromakalim and
diazoxide. These agents open mitoKATP reconstituted from
bovine heart mitochondria with K1/2 values of 1.6 and 0.8
AM, respectively (Fig. 1A), and they opened cellKATP
reconstituted from beef heart sarcolemmal membranes with
K1/2 values of 18 and 840 AM, respectively (Fig. 1B). It
should be noted that 800 AM diazoxide is cytotoxic, because
it both uncouples and inhibits mitochondrial respiration at
such high concentrations [4,48].
Our third finding was based on an exploitation of these
pharmacological differences in a study of cardiac ischemia–
reperfusion injury [2]. We found that diazoxide and croma-
kalim were equally effective in protecting the heart from
ischemia– reperfusion injury, as summarized in Fig. 2.
Importantly, protection by the nonselective drug, cromaka-
lim, was accompanied by a marked APD shortening, whereas
the mitoKATP-selective agent, diazoxide, caused no APD
shortening, showing that diazoxide was not acting via
sarcKATP. Protection by both drugs was blocked by gliben-
clamide and 5-HD. From this set of results, we concluded
that mitoKATP is the receptor for cardioprotective KATP
openers, a hypothesis that is now widely accepted [9,49–52].
3.2. How is mitoKATP opened by the endogenous signaling
pathways of IPC and CPC?
Cardioprotection by IPC and CPC is blocked by inhib-
itors of mitoKATP, such as 5-HD and glibenclamide. This
indicates not only that mitoKATP is involved in these modes
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endogenous mechanisms. Since many protein kinases are
activated during IPC, we hypothesize that mitoKATP is
modified in vivo by phosphorylation, leading to a sustained
open state [1].
3.3. Is mitoKATP involved in all modes of cardioprotection?
We have seen that mitoKATP plays the key role in cardi-
oprotection by all three modes of acute preconditioning—
IPC, CPC, and KCO cardioprotection. What is known about
the other four modes of protection described in Section 2.1?
The evidence is reasonably clear that mitoKATP is involved in
delayed preconditioning [53,54] and APC [55,56]. Miura et
al. [57] have concluded that mitoKATP also plays a role in
cardioprotection by Na+/H+ exchange inhibition. Experi-
ments have not yet been performed to determine whether or
not mitoKATP is involved in ischemic post-conditioning.
3.4. During which phase is mitoKATP opening crucial for
cardioprotection?
Experimental ischemia–reperfusion studies can be divid-
ed into three phases, as shown diagrammatically in Fig. 3.
The preconditioning phase begins 15–30 min prior to the
test ischemia. The ischemic phase is typically of 30 min
duration in the perfused rat heart. Increased time to ischemic
contracture, which indicates significant conservation of ATP
in the protected heart, is the first indication of protection
during ischemia. Most assays for protection are performed
during the reperfusion phase. Recovery of contractile func-
tion and reduced enzyme release due to sarcolemmal dam-
age are detected early, and infarct size is commonly
measured several hours after reperfusion. Additional assays
include recovery of high-energy phosphates [29,58] and
outer mitochondrial membrane permeability to cytochrome
c and ADP, performed on saponin-skinned fibers [5,59].
In which of these phases does mitoKATP opening play its
protective role? There is good evidence that mitoKATP is an
intrinsic component of the signaling pathways that are
activated during the preconditioning phase and that mito-
KATP opening also plays a critical role during the ischemic
phase. We propose that mitoKATP opening may also be
important during the initial stages of reperfusion. Thus,
mitoKATP opening exerts effects that are temporally distinctFig. 3. The three phases of ischemia– reperfusion studies. MitoKATP is
proposed to play distinct roles in each phase of ischemia– reperfusion—
preconditioning, ischemia, and reperfusion (see text).as a trigger of cardioprotection (during the preconditioning
phase) and as an end effector of cardioprotection (during the
ischemic and reperfusion phases). As discussed later, these
effects are also mechanistically distinct.
3.4.1. MitoKATP opening as a trigger of cardioprotection
during the preconditioning phase
The role of mitoKATP opening in the preconditioning
signaling pathway is to increase mitochondrial production
of ROS [3]. The finding that mitoKATP opening leads to a
moderate increase in mitochondrial ROS production in
cardiomyocytes [3,60] has been confirmed in vascular
smooth muscle cells [61] and perfused hearts [62,63]. It is
entirely consistent with earlier studies showing that scav-
enging ROS blocks cardioprotection [51,64–66]. As dis-
cussed in Section 4.1.3., the role of ROS is to activate
kinases within the cardioprotective signaling pathway.
3.4.2. MitoKATP opening as an end-effector of
cardioprotection during the ischemic phase
The target of cell signaling is an end effector of cardi-
oprotection, one or more cellular elements, or processes that
are altered to protect the heart during ischemia and reperfu-
sion. We proposed that mitoKATP is the end effector of
cardioprotection [2], and many studies show that mitoKATP
is required to be open during the ischemic phase [52,67–
70]. Results of a study by Tsuchida et al. [69] are particu-
larly convincing in this regard. They show that diazoxide
reduced infarct size even when administered after the onset
of ischemia, provided that diazoxide was added before the
development of necrosis.
In an important paper, Pain et al. [51] showed that
mitoKATP opening triggers the preconditioned state and that
protection persisted despite wash-out of diazoxide. 5-HD
blocked protection when added prior to 5 min of precondi-
tioning ischemia or prior to diazoxide; however, it did not
block protection when added 5 min prior to the index
ischemia. The results of these studies led the authors to
conclude that mitoKATP acts to trigger protection but is not
an end effector of protection. This conclusion conflicts with
those of the preceding paragraph. However, there are two
possible explanations for the failure of 5-HD to block
protection when added after preconditioning ischemia or
diazoxide. First, when mitoKATP is opened by endogenous
mechanisms, the open state may be less susceptible to
inhibition by 5-HD. We have previously reported state-
dependent inhibition of mitoKATP by glibenclamide and 5-
HD [47]. Indeed, Wang et al. [67] found that 5-HD did
block protection when added 5 min prior to ischemia, but
that this blockade required a higher dose. Secondly, there
may be a pharmacokinetic limitation—5 min may not be
sufficient for 5-HD to reach its intracellular target. For
example, Kouchi et al. [43] found in thoracotomized rabbits
that glibenclamide blocked the protection of IPC and CPC
when administered 30 min, but not 5 min, prior to the
preconditioning step. We have investigated this issue in
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ischemic periods, each followed by 5 min reperfusion, was
blocked by 300 AM 5-HD added 10 min prior to the test
ischemia. Accordingly, we conclude that mitoKATP is an end
effector of cardioprotection.
The identity of the proximate end effect that causes
ischemia–reperfusion injury is not entirely clear. One can-
didate is the mitochondrial permeability transition (MPT)
[71], which opens upon reperfusion [72,73] and subsequent-
ly triggers damage to the sarcolemmal membrane [74] and
causes cell death [75]. MPT is not a specific channel, but
rather the consequence of oxidative damage to membrane
proteins, notably the adenine nucleotide transporter. Al-
though this field is controversial, the important work of
Vercesi et al. (reviewed in Ref. [76]), indicates the following:
(1) The primary role of matrix Ca2 + is to stimulate ROS
production upon reperfusion. (2) Ca2 + cannot open MPT
unless thiol oxidizing reagents (ROS) are present. (3) Cyto-
solic Ca2 + (which is elevated after ischemia–reperfusion)
may play an additional role in promoting ROS oxidation of
adenine nucleotide translocase (ANT) with formation of
MPT. These conclusions imply thatmitochondrial protection
during ischemia is critical for cardioprotection, because MPT
does not open in normal or protected mitochondria.
There is considerable evidence for preconditioning-in-
duced mitochondrial protection during ischemia. IPC and
KCO protection reduce the rate of ATP loss during ischemia
in vivo [29,58,77]. Mitochondrial DW is lower in protected
hearts during ischemia, leading to reduced Ca2 + accumula-
tion [78,79], which has been identified by several laborato-
ries as being important for cardioprotection [49,80].
Perhaps the most important factor conferring protection
is preservation of cellular adenine nucleotides, because this
assures sufficient ADP for an appropriate response during
reperfusion and avoidance of the compromised state leading
to increased ROS. Indeed, Jennings et al. [81] have shown
that adenine nucleotides are rapidly degraded during ische-
mia and that IPC retards the rate of degradation. As
discussed in Section 4.2., we hypothesize that an open
mitoKATP preserves the structure–function of the IMS and
maintains the low permeability of the outer membrane to
adenine nucleotides, thereby preserving ADP for phosphor-
ylation upon reperfusion.
3.4.3. MitoKATP opening as an end-effector of
cardioprotection during the reperfusion phase
Reoxygenation of the ischemic heart is associated with a
burst of ROS that occurs within moments of reperfusion
[82]. Bolli et al. [83] showed that the intensity of ROS
generation is related to the severity of ischemia, that ROS
contribute to the persistent contractile dysfunction (myocar-
dial stunning) observed after brief ischemia, and that anti-
oxidants given at reperfusion have a beneficial effect on
stunning. In a nice study on chick cardiomyocytes under-
going hypoxia, Vanden Hoek et al. [84] also demonstrated a
transient ROS burst upon reoxygenation. The ROS burstwas blocked, and the cells were protected, by IPC. These
protective effects were abolished by 5-HD. The ROS burst
was also blocked by antioxidants or pinacidil given at the
time of reperfusion. These findings indicate that IPC, which
itself causes a moderate ROS increase during the precondi-
tioning hypoxia, protects cells by reducing ROS generation
at reperfusion, and that this involves a signaling pathway
that includes mitoKATP. Vanden Hoek et al. [84] point out
that the pharmacokinetics of pinacidil are more favorable in
the cell culture system that they used, which may account in
part for the protection observed when the drug was added
during reperfusion. However, Mizumura et al. [85] observed
reduction in infarct size when bimakalim was administered
just before reperfusion, and Toyoda et al. [70] found that 5-
HD added at reperfusion caused an increase in infarct size in
IPC-treated hearts. These results suggest that mitoKATP
must be open during the reperfusion phase in order to
achieve full protection. As discussed in Section 4.3., we
hypothesize that an open mitoKATP during reperfusion
facilitates rapid energy conversion to phosphocreatine
(PCr). Under these conditions, mitochondria will not pro-
duce a burst of ROS upon reperfusion, and the irreversible
opening of the MPT will not occur.
3.5. The role of mitoKATP opening in apoptosis
Apoptosis is a biochemical process that results in cell
death. Many apoptotic processes originate in mitochondria,
including the release of cytochrome c, which is a caspase-
activating cofactor. Pro- and antiapoptotic members of the
Bcl-2 family regulate cytochrome c release by unknown
mechanisms (for excellent reviews, see Refs. [86–88]).
Anversa et al. [89] found that apoptosis accounted for a
majority of cell death after myocardial infarction. Kang et
al. [90] studied cell death in cardiomyocytes subjected to
hypoxia and reoxygenation and found that necrotic cell
death predominated during the hypoxic phase, whereas
apoptosis predominated during the reoxygenation phase.
Bcl-2 overexpression blocked the cytochrome c release
and activation of caspase-3 and -9. Our laboratory has
shown in isolated perfused rat hearts that ischemia–reper-
fusion causes an increase in outer membrane cytochrome c
permeability without accompanying uncoupling. Both IPC
and diazoxide preconditioning prevented the increase in
cytochrome c permeability, suggesting a role for mitoKATP
in preventing apoptosis associated with ischemia–reperfu-
sion injury [5,59].
Akao et al. [91] carried out a study in which cultured
neonatal rat cardiomyocytes were exposed for 16 h to 200
AM H2O2. The cells exhibited apotosis by the TUNEL
assay, and caspase-3 activation reached a peak in 8 h.
Pretreatment with diazoxide caused these effects to be
attenuated by about 50%, and diazoxide protection was
abolished by 5-HD. Notably, the authors also found that
diazoxide decreased the number of cells undergoing mito-
chondrial depolarization.
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ptosis is provided by the cardioprotective signaling cascade,
which causes activation of many kinases. Outer membrane
permeability to cyt c is controlled by Bcl-2 and Bax
homologs [87,88]. It has been found in some cell types that
cyt c permeability is prevented by phosphorylation of pro-
apoptotic Bid [92].
3.6. The role of mitoKATP opening in ischemic protection in
other tissues
Preconditioning protects a variety of tissues against
ischemia–reperfusion injury. Pang et al. [93,94] showed
that KATP channels are involved in IPC of skeletal muscle.
Several studies have shown that KCOs are protective in
central nervous system models of ischemia–reperfusion
[95–97]. MitoKATP may play a role in brain protection.
We have shown that brain mitochondria contain mitoKATP
and that its properties are similar to those of heart mitoKATP
[98]. In an important study, Domoki et al. [97] showed that
diazoxide protected against neuronal ischemia–reperfusion
injury in neonatal pigs and that the protection was blocked
by 5-HD.4. Mechanisms of cardioprotection induced by mitoKATP
opening
Our views on the mechanisms by which mitoKATP
opening protects the heart derive in large part from experi-
ments studying the bioenergetic consequences of mitoKATP
opening in isolated rat heart mitochondria, as discussed in
Ref. [1]. MitoKATP opening causes a modest increase in K
+
influx that will have two different effects, depending on the
underlying bioenergetic state of the cardiomyocyte:
(a) In the resting cell, mitochondrial DW is high, and
mitoKATP opening will cause net K
+ influx into the
matrix with consequent swelling and alkalinization of
the matrix. The net uptake of K+ salts leads to increased
ROS production.
(b) In the ischemic cell, mitochondria depolarize due to
anoxia. In the reperfused cell, mitochondria also
depolarize, due to high rates of electron transport.
When DW is low, mitoKATP opening adds a parallel K
+
conductance that counteracts the decrease in K+ influx
and matrix contraction that would otherwise occur
[1,4,98]. MitoKATP opening therefore maintains con-
stant volume of the mitochondrial matrix and IMS.
4.1. Preconditioning phase—the mechanism by which
mitoKATP opening triggers cardioprotection
4.1.1. Mitochondrial ROS production
Excessive levels of ROS, including superoxide radical,
hydroxyl radical, and H2O2, are associated with cell dam-age, including ischemia–reperfusion injury and stunning. It
is now clear, however, that moderate increases in ROS play
an important second messenger role in a variety of signaling
pathways essential for cell physiology [99–105]. In partic-
ular, elevated ROS levels in the cardiomyocyte are essential
for activating the signaling pathways leading to cardiopro-
tection against ischemia–reperfusion injury [51,66].
ROS levels in the cell are the result of a balance between
scavenging enzymes and production. A recent paper iden-
tifies the flavin mononucleotide group (FMN) of Complex I
as the physiologically important site of superoxide forma-
tion in brain mitochondria [106]; however, it appears that
mitochondrial ROS originates primarily at Complex III from
reaction of Coenzyme Q intermediates with molecular
oxygen in heart mitochondria [107,108]. In either case,
uncoupling of mitochondria will lead to decreased ROS
production and lower ROS levels [108].
4.1.2. A proposed mechanism for increased mitochondrial
ROS production
When mitoKATP is opened during the preconditioning
phase, there ensues an increase in mitochondrial ROS
(mitoROS) production. The bioenergetic setting is the
quiescent heart, in which DW is high. Under these con-
ditions, mitoKATP opening will cause net K
+ influx, matrix
swelling, and matrix alkalinization [1]. Matrix swelling
appears not to be consequential in this phase, because it is
modest in extent and does not lead to outer membrane
rupture or uncoupling [4]. K+ uptake is driven by electron
transport-driven H+ ejection, creating a gradient for uptake
of Pi on the electroneutral Pi–H+ symporter, the most rapid
anion transporter in mitochondria. Pi uptake will be less
than K+ uptake, because Pi is present in much lower
concentrations than K+. For this reason, matrix pH always
increases when matrix volume increases due to uptake of K+
and Pi [1]. It thus appears that a moderate increase in matrix
pH and ROS production are the primary consequences of
mitoKATP opening in the quiescent heart.
Unpublished experiments on isolated heart mitochondria
indicate that matrix alkalinization and ROS production are
causally related. For example, adding 20 mM ammonium
chloride to the medium, which alkalinizes the matrix due to
nonionic equilibration of ammonia, results in a 50% in-
crease in mitoROS production. It follows that net K+ influx,
which also alkalinizes the matrix, should increase mitoROS.
When respiring mitochondria were titrated with low con-
centrations of valinomycin, ROS production increased with
a peak activity at about 0.8 pmol Val/mg. At higher con-
centrations, ROS production decreased due to uncoupling.
The amount of K+ flux catalyzed by this level of valino-
mycin is very small, as demonstrated by the observation that
respiration was stimulated to a minor extent, about 3–5 ng
atom O/min mg. Indeed, we found that the K+ influx
induced by 0.8 pmol/mg valinomycin is approximately the
same as that induced by mitoKATP opening. This demon-
stration was based on a comparison of the effects of
Fig. 4. Effects of ouabain (Oua), diazoxide (DZX), and 5-HD on ROS
production in cardiac myocytes. Ros production in isolated cardiomyocytes
was measured from the fluorescence of intracellular DCF (2V,7V-dichloro-
fluorescein). See also Tian et al. [60].
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state matrix volume. These preliminary data are consistent
with the view that a modest K+ influx alkalinizes the matrix,
which in turn causes increased ROS production.
4.1.3. The preconditioning signal amplification loop
A cardioprotective signaling pathway is mobilized by all
three modes of preconditioning and has been extensively
studied and reviewed by Downey et al. [109–111]. Precon-
ditioning involves three major components: activation of
membrane receptors and protein kinases, opening of mito-
KATP, and subsequent release of ROS from mitochondria.
For example, the signaling pathway of IPC begins with the
activation of G protein-coupled receptors induced by the
agonists that are released locally during the preconditioning
ischemia, including adenosine, acetylcholine, bradykinin,
catecholamines, angiotensin II, and opioids [66,109]. Re-
ceptor activation triggers a signaling cascade, resulting in
stimulation of a variety of protein kinases such as protein
tyrosine kinases (PTK) [112], protein kinase C (PKC) [113–
115], and mitogen-activated protein kinases (MAPK) [116].
PKC plays an important role in both IPC [113–115] and
CPC [16–18]. There is evidence that a threshold quantity of
various stimuli is necessary in order to activate PKC to a
level sufficient for cardioprotection [117]. Studies using
PKC isoform-specific agonist and antagonist peptides pro-
vide convincing evidence that ePKC activation is required
for cardioprotection [118,119]. Interestingly, Chen et al.
[120] propose that ePKC activation confers protection,
whereas yPKC activation blocks protection.
Downey et al. [121,122] have focused on the important
question of the mechanism responsible for the memory
exhibited by IPC—that is, what holds the preconditioning
signal for about 1 h between the short ischemia and the
index ischemia? Inhibitors of PKC and PTK were found to
block protection only when they are present during the
index ischemia, suggesting that the memory occurs prior to
protein phosphorylation. This group has suggested that the
memory resides in the translocation of PKC to its RACK
(Receptor of Activated C Kinase), that this translocation
occurs as a consequence of the preconditioning ischemia,
and that kinase activity is initiated during the index ischemia
[123].
Involvement of PTKs including Src in IPC has also been
well documented (16–18). Src family kinases are 52–62 kDa
membrane-associated nonreceptor tyrosine kinases (RTKs)
that are key regulators of various signal transduction path-
ways [124–127]. Src, for example, plays an important role
not only in the signal transduction pathways of growth
factors, but also in coupling stimulation of other receptors
and cellular stress to RTKs [124–127]. Furthermore, there is
strong evidence that activation of Src contributes significant-
ly to hypertrophic growth in cardiac myocytes [128,129].
Recently, Ping et al. [130–132] have demonstrated that IPC
activated Src in the rabbit heart and that inhibition of Src
blocked IPC. Significantly, they showed that IPC as well asnitric-oxide-induced late preconditioning induced the forma-
tion of a signaling module consisting of ePKC, Src, and
several other proteins. Activation of ePKC was essential for
the formation of this signaling module and activation of Src
[132]. These studies not only confirmed the role of Src in IPC,
but also linked Src to PKC activation. However, it is still not
clear how extracellular stimuli transduce the signal to the
PKC–Src complex, and how the PKC–Src signal is trans-
mitted to mitoKATP. Korge et al. [133] report indirect evi-
dence that phorbol 12-myristate 13-acetate, a PKC activator,
opens mitoKATP in isolated rat heart mitochondria.
Na/K-ATPase hydrolyzes ATP to maintain the transmem-
brane gradients of Na+ and K+ found in most mammalian
cells and is inhibited specifically by cardiac glycosides such
as ouabain [134–136]. Recently, we showed that in addition
to pumping ions, the Na/K-ATPase interacts with neighbor-
ing membrane proteins and organized cytosolic cascades of
signaling complexes to send messages to various intracel-
lular organelles [137]. The signaling pathways that are
rapidly elicited by the interaction of ouabain with the
enzyme were initiated by Src binding to the Na/K-ATPase,
which resulted in Src activation and transactivation of the
EGFR. The downstream events related to these signals
include activation of Shc, phospholipase C-gamma/PKC
isozymes, Ras/p42/44 MAPKs, p38, increases in intracellu-
lar concentrations of ROS, [Ca2 +]i and contractility, induc-
tion of some of the early response protooncogenes, and
activation of transcription factors AP-1 and NF-nB [60,105,
138–141]. Interplays among these pathways eventually
result in changes in the expression of a number of cardiac
growth-related genes and stimulation of protein synthesis
and myocyte hypertrophy [137].
Interestingly, as shown in Fig. 4, ouabain-induced ROS
production originated from mitochondria and required open-
ing of mitochondrial KATP since preincubation of cardiac
myocytes with 5-HD blocked ouabain-induced ROS pro-
duction [60,140]. In addition, inhibition of Src by either
herbimycin A or PP2 completely blocked ouabain-induced
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tion also required Ras activation [140]. Because ouabain
activated Raf in cardiac myocytes, we propose that extra-
cellular ouabain may transmit its signal to mitoKATP through
the Src/Ras/Raf cascade (as diagrammed in Fig. 5) since Raf
isoforms have been localized in mitochondria [142,143],
where they play a role in regulation of apoptosis [144].
Because the above ouabain-activated pathways bear a strong
resemblance to those activated during IPC, we recently
tested if ouabain can protect cardiac myocytes as well as
perfused heart from ischemia-induced cell death. These
studies demonstrated that nontoxic concentrations of oua-
bain exhibited a similar protection against ischemia as IPC
in both the perfused heart model (P. Dos Santos, unpub-
lished studies) and isolated cardiomyocyte model (D. Van
Winkle, unpublished studies). In the latter model, inhibition
of Src by PP2 or herbimycin A completely abolished
ouabain-induced protection. Pretreatment of myocytes with
5-HD also caused a significant repression of ouabain-in-
duced protection. Clearly, these findings are significant.
First, they confirm the role of Src in IPC, identify the steps
that lead to the activation of PKC and Src, and make a
connection between Src activation and opening mitoKATP.
Second, we established a clean in vitro model for identifi-
cation of missing linkers between activation of Src and
mitochondrial production of ROS via opening of mitoKATP.
Finally, since digitalis glycosides are still widely used in the
treatment of congestive heart failure, these findings have
clinical implications.
The involvement of mitoKATP in IPC has been exten-
sively discussed in the previous sections. However, the
ability of KCOs such as diazoxide to trigger the cardiopro-
tective signaling pathway [3,51] is intriguing because itFig. 5. The mitoKATP signal amplification loop. The figure illustrates a
hypothetical positive feedback cycle within the cardioprotective signaling
pathway. The three major modes of ischemic protection are IPC (ischemic
preconditioning) CPC (Ca2 + preconditioning), and pharmacological
preconditioning by diazoxide. Ouabain has also been shown to be
cardioprotective (unpublished data). The proposed end result of the loop
is to phosphorylate mitoKATP, putting it in a long-lived open state.implies that mitoROS activate a key kinase in the neigh-
borhood of mitochondria. Under these conditions, mitoKATP
opening appears to be upstream of the above-discussed
kinases. During IPC, cell signaling acts to open mitoKATP
and increase ROS production, indicating that mitoKATP
opening is downstream from the kinases. This apparent
temporal contradiction can be resolved by postulating that
mitoKATP is a component of a signal amplification loop
designed to assure full opening of mitoKATP. As shown in
Fig. 5, there is no distinction between upstream and down-
stream elements in this part of the pathway, and several
turns of the cycle may be required to achieve the end result
of mitoKATP phosphorylation to assure that the channel is
open during the test ischemia. Now, the question is whether
KCO-induced ROS are able to activate the PKC/Src module
and initiate the signaling loop as outlined in Fig. 5. In this
regard, we recently found that exposure of cardiac myocytes
to diazoxide was sufficient to cause 25% inhibition of Na/K-
ATPase in a time-dependent manner in cardiac myocytes
(unpublished data). These data suggest that diazoxide-in-
duced ROS may transduce its signal in the same manner as
oaubain, through the Na/K-ATPase to the PKC/Src module,
followed by initiation of the signal amplification loop.
4.2. Ischemic phase—the mechanism by which an open
mitoKATP protects the heart during ischemia
4.2.1. Outer mitochondrial membrane permeability to
adenine nucleotides
Rostovtseva and Colombini [145] have shown that the
voltage-dependent anion channel (VDAC) controls outer
membrane permeability to ADP and ATP. In heart, VDAC
is normally in a low-conductance state that is poorly perme-
able to nucleotides, and energy transfers between mitochon-
dria and cytosol are mediated instead by creatine and creatine
phosphate [146]. Octamers of mitochondrial creatine kinase
(Mi–CK) bridge the IMS between outer membrane VDAC
and the inner membrane ATP/ADP translocator (ANT)
[147,148], and it has been shown that Mi-CK binds to
VDAC [149]. We hypothesize that binding of octameric
Mi-CK to VDAC confers a low outer membrane conduc-
tance to nucleotides and that this binding requires a narrow
intermembrane distance. During ischemia, DW will decrease,
and the balance of the K+ cycle will shift to efflux and matrix
contraction. The resulting expansion of the IMS will cause
Mi-CK to dissociate from VDAC, leading to a high outer
membrane conductance to ATP and ADP. If mitoKATP is
open during ischemia, normal matrix and IMS volumes will
be maintained, and the outer membrane will retain its low
permeability to nucleotides. This model is depicted in Fig. 6
(Ischemia).
4.2.2. Preservation of adenine nucleotides and reduced DW
during ischemia
To explore this hypothesis in greater depth, we carried
out a series of measurements of ATP hydrolysis by mito-
Fig. 6. MitoKATP regulation of VDAC permeability to nucleotides during
ischemia and during high rates of ATP production. DW is supported by ATP
hydrolysis during ischemia and by electron transport during the high work
state. Both of these stresses will cause a decrease in DW, resulting in
reduced uptake of K+ salts and water, contraction of the matrix, and
expansion of the IMS. This structural change can be prevented by a
compensatory increase in K+ conductance mediated by opening mitoKATP.
If mitoKATP is blocked or does not open, the IMS expansion results in
increased outer membrane permeability to ATP and ADP. During ischemia,
this means that all of cellular ATP is available for hydrolysis by
mitochondria, with consequent degradative loss of adenine nucleotides,
and, ultimately, unavailability of ADP for rephosphorylation upon
reperfusion. During the high work state, increased VDAC permeability to
ADP and ATP constitutes a diversionary leak in the system away from the
more efficient metabolic channeling through mitochondrial creatine kinase
(‘‘CK’’). Consequently, If mitoKATP is blocked, mitochondria cannot
supply ATP at the high rates required, and the heart cannot respond to
inotropic stress.
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ischemia). Following is a brief summary of the results of
these studies, which are described in Dos Santos et al. [5]:
About 55% of total ATP was hydrolyzed in 90 s in untreated
mitochondria, and a combination of diazoxide and mild
osmotic swelling reduced this value to 15%. After the outer
membrane was ruptured by matrix swelling, ATP hydrolysis
returned to control values (55%) and was no longer sensitive
to changes in matrix volume. These findings support the
hypothesis that IMS volume regulates ATP hydrolysis and
show (1) that opening mitoKATP reduces ATP hydrolysis;
(2) that this effect is due to small changes (about 15%) in
mitochondrial volume; and (3) that an intact outer mem-
brane is necessary for the effect. Ozcan et al. [68] have also
shown reduced ATP hydrolysis in isolated mitochondria
treated with diazoxide.The mechanism of reduced ATP hydrolysis requires
further scrutiny. Clearly, the rate of ATP hydrolysis in
these experiments depends on the rate of ion leak across
the inner membrane, and any effect of outer membrane
permeability to ATP can only be indirect. Ion leak is
determined by DW, which in turn is in equilibrium with
the mitochondrial phosphorylation potential, DGP. As
|DGP| falls, due to consumption of ATP, DW will decrease
and ion leaks will decrease. When VDAC is open during
ischemia (mitoKATP closed, matrix contracted, IMS ex-
panded), nucleotide equilibration across the outer mem-
brane will make all of the ATP available to support ATP
hydrolysis. The rate of decrease in DW will be slow
during in vitro experiments, because total ATP is very
high (infinite bath). When VDAC is closed during ische-
mia (mitoKATP open, matrix expanded, IMS contracted),
nucleotides cannot equilibrate rapidly across the outer
membrane. In this condition, the primary supply of ATP
is limited to the IMS, and DGP is no longer in equilibrium
across the outer membrane. |DGP|mito and DW will de-
crease much more rapidly, ion leaks will decrease corre-
spondingly, and ATP hydrolysis will be much slower, as
observed. Confirming this view, we observed that DW
declined much more rapidly when ATP hydrolysis was
inhibited by mild matrix swelling, as shown in Dos Santos
et al. [5]. Thus, the reduced ATP hydrolysis derives from
segregation of ATP and DGP between the mitochondrial
and external compartments. This segregation depends on
VDAC permeability, which, in turn, depends on the
volume of the IMS. It should be emphasized that these
findings exclude uncoupling as a cause of the more rapid
depolarization of DW, because uncoupling would increase
ATP hydrolysis, whereas we observed decreased ATP
hydrolysis.
These findings support a plausible mechanism by which
mitoKATP opening during ischemia, through its effect on
IMS volume, (1) reduces the rate of ATP loss; (2) reduces
the rate of adenine nucleotide degradation so that ADP is
available for phosphorylation upon reperfusion; and (3)
reduces DW and Ca2 + accumulation, preventing Ca2 +
overload. These effects preserve mitochondria so that they
can return upon reperfusion to their normal function of
providing adequate ATP supply to cytosolic ATPases.
4.3. Reperfusion phase—the mechanism by which mitoKATP
opening preserves energy transfer and improves functional
recovery at reperfusion
4.3.1. Energy transfers between mitochondria and cytosol
in heart
Energy transfer from mitochondria to myofibrils and
SERC-ATPase is mediated by two parallel pathways—
creatine/creatine phosphate (Cr/CrP) and ATP/ADP. Cr/
CrP is the more efficient of the two and inhibition of this
pathway prevents the heart from working in the upper 50%
of its range [150–152]. About 67% of the energy produc-
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[153]. Tian and Ingwall [154] and Saks et al. [151] showed
that inhibition of CK in heart causes a profound decrease in
rate-pressure product in response to Ca2 +. Thus, when the
myocyte must rely solely on ADP diffusion to mitochon-
dria, it can no longer maintain high rates of ATP synthesis
and consumption [151,152,155].
In the Cr/CrP system, myofibrillar creatine kinase (MM-
CK) converts ADP to creatine, which diffuses to the
mitochondrial IMS. Octamers of Mi-CK bridge the IMS
between outer membrane VDAC and inner membrane ATP/
ADP translocator (ANT_ [147]. The Mi-CK reaction is very
rapid. Cr combines with ATP as it leaves the matrix, and the
ADP formed is simultaneously taken up by ANT for
rephosphorylation. In this way, Cr input is immediately
followed by CrP output, so that ATP and ADP are only
involved at the source (ATP synthase) and sink (myofibril
ATPase) of the cycle [151,152,155,156]. VDAC has a low
permeability to ADP and ATP in vivo, and the amplifying
effect of the Mi-CK system permits very high rates of
respiration, even at low ADP concentrations [157]. These
features permit |DGP| to be maintained at high levels in the
face of high ATPase activity. If, however, the architecture of
the IMS is perturbed by detachment of Mi-CK from the
mitochondrial membranes, this control is lost [158].
The efficiency of this energy transfer system requires
adenine nucleotide compartmentation, which, in turn,
requires low permeability of the outer mitochondrial
membrane to adenine nucleotides. As in the preceding
section, we hypothesize that binding of octameric Mi-CK
to VDAC is responsible for maintaining low adenine
nucleotide permeability and that this binding requires a
narrow intermembrane distance. During reperfusion, DW
will be low due to high rates of electron transport, and the
balance of the K+ cycle will shift to efflux and matrix
contraction. The resulting expansion of the IMS will cause
Mi-CK to dissociate from VDAC, leading to a high outer
membrane conductance to ATP and ADP. If mitoKATP is
open during ischemia, normal matrix and IMS volumes
will be maintained, the outer membrane will retain its low
permeability to nucleotides, and the mitochondria can
restore energy levels using the more efficient metabolic
channeling via Mi-CK. This model is depicted in Fig. 6
(High Work).
It should be noted in this regard that Saks et al. [146,157]
and Toleikis et al. [159,160] have observed in saponin-
skinned fibers that the normally high K1/2 (ADP) is sharply
reduced by controlled proteolysis. Saks et al. has concluded
that outer membrane nucleotide permeability is controlled
by intracellular attachments to cytoskeleton. The extent to
which this proteolysis occurs in vivo is not known, but such
a modification may occur during chronic ischemia or
apoptosis. We do not view these two distinct mechanisms
of regulating VDAC permeability as being mutually exclu-
sive: volume regulation occurs on short time scales and
regulation by proteolysis occurs on long time scales.4.3.2. Preservation of nucleotide compartmentation by
opening mitoKATP
We examined outer membrane nucleotide permeability in
permeabilized fibers taken at the end of ischemia–reperfu-
sion [5,59]. Thirty-minute ischemia caused a decrease in the
K1/2 (ADP) for respiration, which reflects an increased outer
membrane permeability to ADP. IPC and diazoxide pre-
vented this ischemia-induced change in mitochondrial func-
tion, and 5-HD blocked the protective effects of IPC and
diazoxide. We also examined whether small changes in
matrix and IMS volumes affect ADP permeability in the
permeabilized fibers from normal perfused rat hearts. In this
preparation, we found that the normally high K1/2 (ADP)
[59] was reduced by 70% by the addition of a very low
concentration (8 nM) of nigericin, which had no effect on
respiration per se, but was sufficient to contract the mito-
chondrial matrix [5]. These studies support the hypothesis
that VDAC permeability to ADP in situ is controlled by
IMS volume. We note that the ischemia-induced change in
the K1/2 (ADP) reflects an alteration of energy transfer from
the mitochondrial matrix to ATP-utilizing sites in the cytosol
that may contribute to the poor functional recovery of
ischemic hearts.
We next examined the effects of small changes in matrix
and IMS volumes on K1/2 (ADP) in isolated rat heart
mitochondria. We observed that isolated mitochondria ex-
hibit a low K1/2 (ADP) (100 AM) when incubated in
isoosmotic media, even in the presence of polyethylene
glycol to reduce IMS volume [161]. Recall, however, that
the matrix of isolated mitochondria is artifactually con-
tracted due to loss of K+ salts during isolation [1,5]. When
matrix volume was increased by a combination of diazoxide
and osmotic swelling, K1/2 (ADP) increased to 275–325
AM. When matrix swelling was sufficient to break the outer
membrane, the volume effect disappeared and K1/2 (ADP)
became independent of matrix volume [5,162]. These find-
ings show (1) that opening mitoKATP affects nucleotide
compartmentation; (2) that this effect is due to small
changes in mitochondrial volume; and (3) that an intact
outer membrane is necessary for the effect. Note that these
conclusions parallel those drawn for ATP hydrolysis in the
previous section.
If the myocyte survives ischemia, it is subjected to new
stresses upon reperfusion. PCr has been consumed, ATP is
low, and Na+ and Ca2 + are elevated. In order to correct
these imbalances, mitochondria must be able to supply
ATP at a high |DGP| to the cytosol. If oxidative phosphor-
ylation is sluggish, reintroduction of oxygen will lead
instead to high rates of potentially deleterious mitoROS
production. When mitoKATP is open during reperfusion, the
association of Mi-CK with VDAC will be preserved,
preventing leaks of ATP and ADP through VDAC and
permitting direct energy transfers through the creatine–PCr
system. This more efficient system may be required
to support energy transfers at high rates at the time of
reperfusion [151,152].
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Man, with his susceptibility to coronary artery disease,
is subject to repeated bouts of ischemia. For this reason, it
is conceivable that cardioprotection by IPC may have
evolved as a specific protective mechanism. However,
IPC appears to exist in all mammalian species, including
those that are not subject to ischemic heart disease.
Therefore, it seems unlikely that preconditioning evolved
specifically to increase resistance to ischemia and more
likely that protection is a beneficial consequence of trig-
gering normal physiological responses. Accordingly, it is
important to develop an understanding of how mitoKATP
participates in normal cardiac physiology. This subject is
being actively investigated by our laboratories, and we will
summarize our preliminary findings.
5.1. The role of mitoKATP in physiological cell signaling
New results indicate that mitoKATP plays a role in
normal cell signaling processes leading to cell growth.
Xie et al. [105,138,140] have shown that binding of
ouabain to Na/K-ATPase activates multiple signal transduc-
tion pathways in cardiac myocytes, including increased
mitochondrial production of ROS, rise in [Ca2 +]i, and
activation of PKC and MAP Kinases. Furthermore, inter-
plays among these pathways in cardiac myocytes leads to
hypertrophic growth and changes in the expression of
multiple growth-related genes. Mitochondrial ROS were
shown to be essential second messengers within this sig-
naling pathway, and recent work has shown that the ouabain
signaling pathway is blocked not only by antioxidants but
also by 5-HD (Fig. 4) [60], thereby linking mitoKATP to cell
growth and hypertrophy. Some elements of the ouabain
signaling pathway overlap with those involved in the
signaling pathway of preconditioning, including Src and
PKC [139,141], and we have preliminary evidence that
pretreatment with ouabain is cardioprotective (Dos Santos,
Van Winkle, Laclau, Garlid, and Xie, unpublished results).
5.2. The role of mitoKATP opening in positive inotropy–
energy transfers between mitochondria and cytosol
When the cardiomyocyte is undergoing high rates of ATP
production and consumption, electron transport is high and
DW decreases—as with any battery system, drawing high
currents will decrease the output voltage. Exactly as hy-
pothesized for cells undergoing ischemia– reperfusion,
mitoKATP opening adds a parallel K
+ conductance that
counteracts the decrease in K+ influx and matrix contraction
that would otherwise occur, resulting in constant volume
and maintenance of a constant uptake of K+ salts [4,98].
Because there is no net change in volume, there is no
increase in ROS production during the high work state.
Upon consideration of the mechanisms described in
Sections 4.2 and 4.3, we propose that endogenous signalsopen mitoKATP during high work states of the heart. This
preserves the structure–function of the IMS and, in par-
ticular, the association of Mi-CK with VDAC. MitoKATP-
dependent volume regulation will thus prevent excessive
leaks of ATP and ADP through VDAC, and energy trans-
fers will occur primarily through the creatine–PCr system.
This more efficient system is thought to be required to
support energy transfers at high rates [151,152]. This
mechanism is modeled in Fig. 6 (High Work).
We have explored this hypothesis in human atrial
fibers [39] and perfused rat hearts. Our preliminary results
show that increased work states in heart cannot proceed if
mitoKATP is blocked. We examined the role of mitoKATP
in the response to calcium-, ouabain-, and dobutamine-
induced positive inotropic stress in Langendorff perfused
rat hearts and correlated these results with an examination
of mitochondrial function in permeabilized fibers from the
same hearts. To test the hypothesis that mitoKATP opening
is required for the positive inotropic response, we exam-
ined the effects of two mitoKATP inhibitors, 5-HD and
tetraphenylphosphonium cation (TPP+) [1]. In support of
the hypothesis, these mitoKATP blockers prevented the
inotropic response (Dos Santos and Garlid, unpublished
results). Moreover, this effect was reflected in an in-
creased permeability of VDAC to ADP, as predicted.
Thus, the K1/2 (ADP) was sharply reduced by both 5-
HD and TPP+. These findings support the views of Saks
et al. [151], in which metabolic channeling through
mitochondrial creatine kinase is essential for the high
work state. Thus, the system can only operate efficiently
if leaks of ADP and ATP across the outer membrane are
minimized, in this case by volume regulation of the IMS.
These results indicate for the first time a physiological
role for mitoKATP in inotropy and, by extension, in heart
failure.
5.3. The role of mitoKATP opening in positive inotropy-
volume regulation of electron transport
Lehninger and Kennedy [163] observed in 1948 that
substrate oxidation is affected by matrix volume, and
Nicholls et al. [164] showed that the effect is independent
of the means used to change volume. Volume activation of
electron transport has subsequently been demonstrated in
liver, heart and, brown adipose tissue mitochondria [165–
167]. The effect of volume on fatty acid (FA) oxidation is
so pronounced that rates are nearly zero when the matrix is
contracted. Volume-activation appears to play an important
role in hormone-stimulated gluconeogenesis and FA oxi-
dation, and stimulation of FA oxidation can be mimicked
in hepatocytes by increasing matrix volume with low doses
of valinomycin [167,168]. Activated electron transport is
needed during states of high ATP demand, but these states
are associated with a decrease in DW. MitoKATP opening
preserves the activated state that would otherwise be lost
due to matrix contraction.
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6.1. The pharmacological approach to mitoKATP function
Pharmacological agents have proved historically to be
the most powerful tools for identifying cardiac receptors and
characterizing their cellular function. MitoKATP is no ex-
ception in this regard: The discovery that mitoKATP may be
the pivotal receptor for the cardioprotective effects of KCOs
was based on the selective pharmacology of diazoxide and
5-HD [2]. Site selectivity is an important aspect of the
pharmacological approach, and is discussed further in Sec-
tion 6.2.
The true power of the pharmacological approach resides
in the fact that mitoKATP openers and blockers are chemi-
cally diverse. Chemical diversity allows us to address the
question of multiple sites of drug action, because differences
in chemical structures render unlikely the possibility that the
cardioprotective actions of all agents are due to non-mito-
KATP interactions within the cell. MitoKATP openers and
blockers are hydrophobic, and it is generally the case that
hydrophobic molecules will inhibit various respiratory chain
complexes at high concentrations. Some agents will also
possess intrinsic uncoupling activity. Thus, pinacidil and
diazoxide have been shown to be mild inhibitors of respi-
ration and to have intrinsic protonophoretic (uncoupling)
properties as a function of concentration [4,48]. However,
these effects occur at doses much higher than those required
to open mitoKATP [4].
The power of the pharmacological approach is often
overlooked, as for example, in the reports of Halestrap
[169] and Daut [170,171] and their coworkers, which are
discussed in more detail in Section 6.3. These papers focus
primarily on diazoxide, which misses the point of the
pharmacological approach. It is reminiscent of arguments
during the 1960s that the mechanism of action of uncouplers
was due to their ability to inhibit respiration, and not due to
their protonophoretic activity. Mitchell [172] pointed out
that the hydrophobic sites of the electron transport chain are
famously sensitive to a wide variety of hydrophobic agents.
He then wrote: ‘‘It would seem that inhibitory and compet-
itive effects of hydrophobic substances on the . . . reactions
of oxidative phosphorylation may often require no more
than trivial explanations’’ [172]. The same statement may be
applied to the claims that diazoxide and pinacidil act by
inhibiting elements of the respiratory chain.
Stereospecificity is another powerful tool that is being
explored in ongoing experiments. For example, Grover et al.
[29] showed that the cardioprotective effects of cromakalim
are steroselective. We have subsequently observed that the
active enantiomer, levcromakalim, opens reconstituted mito-
KATP with K1/2 of 1.6 AM, whereas the inactive enantiomer
had no effect on mitoKATP. These findings are intrinsically
important in linking mitoKATP to cardioprotection. They
also suggest a straightforward approach to the question of
whether protection is caused by respiratory inhibition,because active and inactive enantiomers are likely to be
equipotent in their non-mitoKATP effects on mitochondria,
including inhibition and uncoupling.
6.2. Pharmacological studies to distinguish between
mitoKATP and sarcKATP in perfused hearts
The hypothesis that mitoKATP, and not sarcKATP, is the
receptor for cardioprotective KCOs has been examined
using the site-specific agents, diazoxide, and BMS191095.
Thus, diazoxide was found to act on mitoKATP, but not
sarcKATP [2]. The experimental KCO, BMS 191095, is
cardioprotective without affecting sarcKATP or vascular
smooth muscle KATP channels [173]. BMS191095 opened
mitoKATP with K1/2 of 83 nM and is a good alternative to
diazoxide for experimental studies. It is expected that
additional site-selective openers and blockers will be iden-
tified in the future.
In our studies, we have found that all known cardiopro-
tective KCOs open mitoKATP within their cardioprotective
dose ranges (Paucek and Garlid, unpublished data). For
example, nicorandil is cardioprotective [174] and opens
mitoKATP with K1/2 = 5 AM. P1075, a potent cyanoguani-
dine, is cardioprotective in isolated, perfused rat heart
[175,176] and rabbit heart [177], with protection being
blocked by 5-HD and glibenclamide. P1075 opens mito-
KATP from rat and rabbit heart mitochondria with K1/2 of
about 70 nM [176,177]. These agents, along with cromaka-
lim and other members of its class, are nonselective and
open both mitoKATP and sarcKATP.
How can we determine the cardioprotective receptor site
for nonselective KCOs? The ideal approach is to combine a
nonselective KCO with a sarcKATP-selective inhibitor, such
as HMR1098 [178]. Thus, Fryer et al. [179] showed that
HMR1098 does not block IPC, confirming the hypothesis
that IPC requires mitoKATP opening. Moreover, Das and
Sarkar [180] have recently shown that HMR1098 does not
block protection by cromakalim or nicorandil, indicating
that these two nonselective agents are protecting the heart
via mitoKATP.
These findings suggest a general approach to identifying
the receptor for cardioprotection by nonselective KCOs;
however, perfused heart studies are not sufficient for such
studies. It is also necessary to test each combination on
mitoKATP activity in vitro. A good example of this necessity
is given by our experience with diazoxide. We were sur-
prised to find that diazoxide protection is blocked by
HMR1098 [61]. New studies on cardiac mitoKATP have
revealed the reason for this apparent paradox: HMR1098
selectively inhibits the diazoxide-opened mitoKATP (Kif 3
AM), but has no effect on the cromakalim- or nicorandil-
opened mitoKATP (Costa and Garlid, unpublished data).
This appears to be another example in which the ability of
blockers to inhibit depend on the specific open state of
mitoKATP, as discussed in Jaburek et al. [47]. The interest-
ing anomaly with diazoxide does not detract from the power
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mitoKATP hypothesis of cardioprotection.
6.3. Non-mitoKATP actions of diazoxide, pinacidil, and
5-HD
The laboratories of Halestrap [169] and Daut [170,171]
repeated studies carried out by Schafer et al. [181] and
Kowaltowski et al. [4], who showed that diazoxide inhibits
SDH at high concentrations. It was reported that 100 AM
diazoxide inhibited coupled respiration in submitochondrial
particles (SMPs) by about 45%. However, this assay is not a
pure measure of enzyme inhibition, because the coupling
membrane imposes restraints such that state 4 respiration is
very sensitive to inhibitors. A more accurate assay is carried
out on uncoupled or state 3 rates, where these restraints are
removed. Such experiments were performed on rat heart
mitochondria, in which we found that 1 mM diazoxide, the
highest concentration tested, inhibited uncoupled respiration
by less than 15% [4]. Thus, diazoxide is a very weak
inhibitor of SDH.
Halestrap and Daut concluded that cardioprotection by
diazoxide is mediated by respiratory chain inhibition [169–
171]. No evidence whatsoever is provided for this question-
able conclusion. The authors fail to address the question of
whether a small inhibition of cardiac SDH would have any
significant effect on the heart. As discussed in the preceding
section, they fail to take into account the chemical diversity
of KCOs: if cardioprotection is caused by SDH inhibition,
then all cardioprotective KCOs should inhibit SDH. This is
already known to be untrue. The authors extrapolate their
results from in vitro studies on mitochondria or SMPs
without considering the pharmacokinetics of diazoxide in
the heart. In intact tissue, diazoxide will bind extensively to
proteins [182,183] and undergo retarded diffusion to the site
of action. For example, the response of the flavoprotein
fluorescence signal to diazoxide exhibits a very long lag
time of 10–12 min [49], and this latency is eliminated in
saponin-permeabilized cells, with higher diazoxide sensitiv-
ity (Brian O’Rourke, personal communication). Proper
studies should compare inhibition and mitoKATP opening
in the same experimental model. When such studies were
performed in our laboratory, the K1/2 for mitoKATP opening
by diazoxide in isolated mitochondria was 2.3 AM, whereas
mild inhibitory effects were seen at concentrations greater
than 100 AM [162].
The same two laboratories report that 5-HD is converted
to 5-HD-CoA by mitochondria in the presence of CoA and
ATP [169] or in the test tube when fatty acyl CoA synthe-
tase, ATP, and CoAwere added [170,171]. Metabolism of 5-
HD is expected and already known from previous work.
Moritani et al. [184] reported in 1994 that 5-HD has a very
short (7 min) biological half-life in dogs, and Munch-
Ellingsen et al. [185] found that 5-HD blocked protection
by IPC in rabbits when given 2 min before IPC, but had no
effect at the same dose when given 8 min before IPC. As theauthors suggested, this short half-life was probably due to
metabolism. Halestrap [169] and Daut [170,171] and their
coworkers speculate that 5-HD may block cardioprotection
by interfering with cardiac metabolism. There is no basis for
such a conclusion. No reasons were given to explain why
drug metabolism should be of concern in heart studies, nor
is metabolism of 5-HD expected to have any effects on the
heart or on IPC. Moreover, 5-HD metabolism cannot
explain why glibenclamide [2] and HMR1098 [61] blocked
diazoxide protection.
It is important to point out that 5-HD has been shown to
inhibit mitoKATP, both in isolated mitochondria and in
proteolipsomes containing purified, reconstituted mitoKATP
[47]. These experiments were carried out under conditions
where there was no possibility of forming the acyl CoA
derivative of 5-HD. 5-HD is a particularly useful drug for
use in whole hearts for two reasons. It appears to be
innocuous in that it has no effects on the control heart,
and it appears to reach the intracellular site more readily
than sulfonylureas such as glibenclamide.7. Alternative mechanism of protection: uncoupling of
oxidative phosphorylation
7.1. Does mitoKATP opening cause uncoupling in the
normoxic cardiomyocyte?
It has been suggested by several workers that mitoKATP
opening protects the heart by uncoupling due to increased
K+ cycling. Uncoupling is thought to be protective by
virtue of the fact that decreased DW would reduce mito-
chondrial Ca2 + uptake and Ca2 + overload during ischemia
[49,78,80,186–188]. Because this issue is important and
controversial, we will discuss the evidence in some detail.
7.1.1. If K+ flux through mitoKATP were sufficient to
uncouple respiration, the outer membrane would rupture
It is important to recall that the K+/H+ antiporter can only
respond to changes in matrix volume [1]. Therefore, net K+
influx due to mitoKATP opening will cause a shift to a higher
steady state matrix volume [4,46,98]. The IMS is normally
small in vivo, and K+ influx sufficient to cause significant
uncoupling may cause matrix swelling sufficient to break
through the outer membrane. We examined this question
directly by measuring the effects of valinomycin on respi-
ration and matrix swelling (unpublished). First, we found a
dose of valinomycin that is roughly equivalent to mitoKATP
opening; that is, a dose that caused the same increase in
matrix volume and respiration as were observed after
opening mitoKATP. This concentration is 0.6–0.9 pmol
Val/mg protein. We then increased [valinomycin] and ob-
served increased swelling and respiration, as expected. At
about 3 pmol Val/mg protein, we observed a transition in the
light scattering trace that is indicative of outer membrane
rupture, as described in Dos Santos et al. [5]. (Note that
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contracted matrix due to the isolation artifact [5]. Less K+
influx would be required to rupture the outer membrane
under in vivo conditions.) Outer membrane rupture was
confirmed by the finding that addition of cytochrome c,
which had no effect on state 2 respiration below 3 pmol Val/
mg protein, increasingly stimulated respiration above that
concentration. 3 pmol Val/mg protein stimulated respiration
by only 70 ng atom O min 1 mg 1 at 25 jC, a very modest
fraction of the FCCP-uncoupled rate (800 ng atom O min 1
mg 1). We conclude that mitochondrial respiration cannot
be significantly uncoupled by increased K+ flux without, at
the same time, causing rupture of the outer membrane.
7.1.2. K+ flux through mitoKATP is too low to uncouple
respiration
In experimental studies, diazoxide is added to the nor-
moxic perfused heart, in which the mitochondria have a
high membrane potential (DW). Opening mitoKATP under
these conditions will increase futile K+ cycling and dissipate
energy; however, the degree of uncoupling and extent of
depolarization will depend entirely on the magnitude of the
added K+ flux. We measured the effects of ATP, ATP + diaz-
oxide, and ATP + diazoxide + 5-HD on respiration in both
rat heart [4] and rat brain [98] mitochondria. Based on these
studies, the magnitude of K+ flux through mitoKATP is 24–
30 nmol K+ min 1 mg 1 at 25 jC in rat heart mitochon-
dria. Kopustinskiene [183] carried out similar measurements
in rat heart mitochondria utilizing site I substrates at 37 jC.
She observed a difference in State 2 respiration of about 5
ng atom O mg 1 min 1 as the consequence of mitoKATP
opening. Assuming a value of 10 for the H+/O stoichiom-
etry, this implies a rate of 50 nmol K+ mg 1 min 1, which
is in very good agreement with the value we obtained at 25
jC [4]. A respiratory stimulation of 5 ng atom O min 1
mg 1 is a very low rate indeed, considering that rat heart
mitochondria can respire in state 3 at over 1000 ng atom O
min 1 mg 1. Respiratory stimulation of this magnitude
will cause an insignificant decrease in DW. These measure-
ments provide direct evidence against significant uncou-
pling as a consequence of mitoKATP opening; however, they
do rely on extrapolation from mitochondria in vitro to
mitochondria in situ.
7.1.3. MitoKATP opening does not uncouple respiration in
vivo
There is ample experimental evidence that mitoKATP
opening does not uncouple respiration in vivo. In an
important paper, Ovide-Bordeaux et al. [189] confirmed
that diazoxide had no detectable bioenergetic effects in
permeabilized cardiac fibers from normoxic hearts. Law-
rence et al. [190] observed diazoxide cardioprotection in
cardiomyocytes with no detectable change in TMRE fluo-
rescence, as a measure of mitochondrial DW. Similar results
were reported by Carroll et al. [191] using JC1 fluorescence.
Grover et al. [29,192] showed that KCOs in pharmacolog-ical doses have no effect on the cardiac efficiency of oxygen
utilization in the intact heart, thus excluding significant
uncoupling as a consequence of KCO administration.
7.1.4. Uncoupling is inconsistent with ROS production
The finding that mitoKATP opening in vivo causes
increased mitochondrial production of ROS [3,51,60–62]
is incompatible with uncoupling, because mitochondrial
ROS production is decreased by uncoupling [108].
7.1.5. Data showing uncoupling by diazoxide and pinacidil
are independent of mitoKATP
The hypothesis that mitoKATP opening protects by
uncoupling [49] appeared to be supported by findings with
KCOs in isolated mitochondria [193–195]. However, these
findings arose from mitoKATP-independent actions of the
drugs. First, the uncoupling cannot have arisen from mito-
KATP opening because the experiments were carried out
under conditions in which mitoKATP was already open [46].
Second, these studies [193–195] employed KCOs in mas-
sive doses, far in excess of concentrations required to open
mitoKATP. We confirmed that diazoxide and pinacidil at
these doses caused uncoupling and consequent inhibition of
Ca2 + uptake in mitochondria; however, we showed directly
that these drugs possess intrinsic uncoupling activity that
only becomes apparent at excessive concentrations [4]. That
the uncoupling did not arise from mitoKATP opening was
demonstrated directly by showing that an equal uncoupling
effect was observed in TEA+ or Li+ media [4]. This result
has been confirmed by Kopustinskiene et al. [48,196], who
showed that high concentrations of diazoxide and pinacidil
uncouple respiration and that this effect is independent of
K+ flux or mitoKATP. Interestingly, these authors found that
intrinsic uncoupling by these agents was blocked by car-
boxyatractyloside, indicating that the uncoupling is mediat-
ed by drug transport via the ANT, perhaps in a manner
analogous to fatty acid transport by ANT [197].
The preceding evidence may be summarized as follows:
maximal rates of K+ flux through mitoKATP are too low to
cause significant uncoupling under normal conditions.
Moreover, if K+ influx did occur at rates sufficient to
uncouple respiration, mitochondria would lyse upon addi-
tion of a KCO in vivo.
7.2. Does mitoKATP opening cause uncoupling during
ischemia?
The rationale for uncoupling by mitoKATP opening is that
it would protect ischemic tissue against excessive mitochon-
drial Ca2 + accumulation by reducing the driving force for
mitochondrial Ca2 + uptake [49,80,195]. We agree that
mitoKATP opening causes depolarization and reduced Ca
2 +
overload during ischemia. However, we have shown that
these effects do not involve uncoupling, because they are
accompanied by reduced rates of ATP hydrolysis. Uncou-
pling would increase ATP hydrolysis [5]. The proposed
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volume by mitoKATP opening during ischemia, as discussed
in Section 4.2.2.
7.3. Flavoprotein fluorescence as a measure of mitoKATP
opening in cardiomyocytes
Liu et al. [49] introduced a valuable new technique for
detecting mitoKATP opening in intact rabbit ventricular
myocytes. They measured flavoprotein fluorescence, as an
index of mitochondrial redox state, and found that diazoxide
induced reversible flavoprotein oxidation to rather high
levels, when compared to the response to dinitrophenol, a
protonophoretic uncoupler. They concluded that changes in
flavoprotein fluorescence can be used to detect mitoKATP
activity in situ. The authors also proposed that mitoKATP
opening may protect the heart by uncoupling. Although the
latter conclusion may be incorrect, the flavoprotein fluores-
cence technique is nevertheless a promising approach to the
difficult problem of detecting mitoKATP activity in situ.
Marban et al. have published numerous papers using this
approach [49,91,186,198–208].
Given that mitoKATP cannot cause significant uncoupling
in the normoxic cardiomyocyte in vivo, what is the origin of
the flavoprotein redox potential signal? This question has
been clarified by Brian O’Rourke (personal communica-
tion). As predicted from the results in Section 7.1., the
percentage of freshly isolated myocytes showing a net redox
change was small. However, nearly all cells responded when
they were first cultured overnight in the absence of added
substrates. Under these conditions, it is expected that the
redox potential will be affected even by the mild uncoupling
caused by mitoKATP opening. Thus, the assay conditions are
designed to amplify the small signal due to mitoKATP
opening, and thereby to evaluate various agents for their
effects on mitoKATP. This is a reasonable experimental
approach. On the other hand, the results probably should
not be extrapolated to physiological conditions that were
obtained in vivo.
One discrepancy that remains to be resolved is that the
cyanoguanidine KCO, P1075, has been reported to be
inactive with respect to mitoKATP on the basis of flavopro-
tein fluorescence measurements [204]. To the contrary,
P1075 is a potent opener of rat and rabbit heart mitoKATP
(K1/2 = 68 nM), and it is an equally potent cardioprotective
agent in the perfused rat and rabbit heart models [175–177].8. The roles of mitoKATP in heart—overview
Mitochondria are recognized to be important in both
cardiac bioenergetics and cardioprotection against ische-
mia–reperfusion injury. Our broad hypothesis is that cardi-
oprotection utilizes the normal physiological functions of
mitoKATP, and our work indicates that mitoKATP opening has
two different effects on the heart that depend on the under-lying bioenergetic state at the time the channel is opened.
When DW is high, as in the resting heart, mitoKATP opening
leads to increased mitochondrial ROS production, and the
ROS in turn activate kinases within a positive signal ampli-
fication loop (Fig. 4) leading to gene transcription and cell
growth. This signaling pathway is also activated by IPC and
leads to phosphorylation of mitoKATP. The resulting sus-
tained mitoKATP opening is cardioprotective against ische-
mia–reperfusion injury. When DW is reduced, as occurs
during inotropic stress or ischemia, mitoKATP opening pro-
vides matrix volume homeostasis. The additional K+ influx
through mitoKATP compensates for the lower driving force
and maintains matrix and IMS volumes. This is essential for
maintaining an activated electron transport system and a low-
conductance state of outer membrane VDAC. The conse-
quences are nucleotide preservation during ischemia and
efficient energy transfers during the high work state and
during reperfusion after ischemia. These working hypotheses
will be rigorously examined in future work.Acknowledgements
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